26 results about "Human proteins" patented technology

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

This invention discloses recombinant humanized type III collagen, its preparation method, and its applications, belonging to the field of medical materials technology. The amino acid sequence of this recombinant humanized type III collagen is any one of SEQ ID No. 2-6. Compared to traditional extraction methods, the amino acid sequence of this recombinant protein is highly consistent with that of natural human proteins, completely avoiding the biosafety risks of pathogens, prions, etc., that may exist during animal-derived extraction, while also exhibiting lower immunogenicity. Furthermore, this protein effectively maintains the natural biological activity and stability of collagen. When used as a wound dressing, this material can efficiently promote cell migration, spreading, and proliferation, accelerate tissue regeneration and wound healing, while possessing excellent biocompatibility, controllable degradation, and low immunogenicity.

The invention relates to the technical field of spreading modes of human viruses, in particular to a virus spreading mode prediction model based on interaction of virus protein and human protein, a prediction model construction method and a prediction method. The method specifically comprises the following steps: S1, constructing a training data set of a virus transmission mode; s2, based on the data in the S1, obtaining a virus-human protein interaction prediction result, vectorizing the prediction result by using 0 / 1 coding, and constructing a virus-human protein interaction matrix; and S3, using a machine learning algorithm and a feature selection project to construct and train a virus propagation mode prediction model based on the interaction of the virus protein and the human protein. The method for predicting the virus propagation mode of interaction between the virus protein and the human protein is convenient to use and wide in application range; the method is especially suitable for new viruses or unknown viruses which are not fully researched, and can realize efficient and rapid propagation mode identification.

The invention discloses a method and a device for quantitatively analyzing protein by liquid chromatography-mass spectrometry. The method comprises the following steps: carrying out standardized enzyme digestion treatment on a sample; comparing the theoretical enzyme digestion peptide fragment of the protein drug with the human-derived protein database, and excluding all peptide fragments with consistent sequences to obtain candidate characteristic peptide fragments; a multi-blank matrix experiment verifies that a high-specificity characteristic peptide fragment is screened out; a multi-reaction monitoring mode of an ultra-high performance liquid chromatography-triple quadrupole mass spectrometry combined system is utilized, and the characteristic peptide fragment is used as a quantitative standard substance to establish a quantitative detection method of the protein; and calculating the target protein content through a standard curve prepared based on a matrix. The device integrates a sample pretreatment module, a liquid chromatography-mass spectrometry analysis module and a data processing and control module. The method has the advantages of high specificity, high sensitivity, high stability, high flux and the like, and a complete solution is provided for accurate quantification of trace protein in a complex biological matrix.

A method for identifying cell subpopulations associated with disease phenotypes, belonging to the biomedical field. To identify cell subpopulations associated with disease phenotypes, this invention collects single-cell RNA sequencing data of the disease to obtain a single-cell expression matrix, collects the bulk expression matrix of the disease and corresponding phenotypic tags, and downloads human protein-protein interaction data to construct a protein-protein interaction network; extracts gene signature features of cells and samples and maps them to the protein-protein interaction network to form corresponding cell modules and sample modules; calculates the distance between each cell module and each sample module, and determines a set of multiple sample modules as the sample module set of the disease phenotype; calculates the distance between cell modules and the sample module set of the disease phenotype; creates a background distance distribution to evaluate the statistical significance of the distance between cell modules and the sample module set of the disease phenotype, and identifies cells whose distance to the sample module set of the disease phenotype is significantly smaller than the background distance distribution.

The invention discloses a genetically engineered bacterium for preparing a recombinant III-type human-derived protein, a construction method of the genetically engineered bacterium, the recombinant III-type human-derived protein and a preparation method of the recombinant III-type human-derived protein. The genetically engineered bacterium comprises (1) a first expression vector containing nucleic acid molecules for coding recombinant III-type human-derived protein; and (2) a second expression vector comprising a promoter region fragment of a ptsG gene, a promoter region fragment of an rne gene or a promoter region fragment of a combination thereof. According to the genetically engineered bacterium, the yield of the recombinant III-type human-derived protein is remarkably increased, no adverse effect is caused on growth of the strain, and a simple, convenient and universal optimization strategy is provided for industrial efficient production.

The invention provides a network pharmacology-based large model generated traditional Chinese medicine prescription curative effect evaluation method and system, and the method comprises the steps: employing a machine learning model to generate candidate prescriptions, and obtaining all known active components of each traditional Chinese medicine in the prescriptions; predicting human body protein targets corresponding to the patient based on the known active components, and gathering all the human body protein targets to obtain a prescription target set P; obtaining human body protein targets related to the corresponding diseases, and gathering all the human body protein targets corresponding to the diseases to obtain a disease target set D; constructing a protein-protein interaction network; inputting the prescription target point set P and the disease target point set D into a protein-protein interaction network, and constructing a connected sub-network; calculating curative effect indexes of the connected sub-networks; and optimizing the prescription based on the curative effect index to complete the curative effect evaluation of the traditional Chinese medicine prescription. According to the method, calculation and experiments are closely combined, the blindness and the cost of experimental verification are remarkably reduced through a calculation priority strategy, and the research and development efficiency is improved.

The application discloses application of recombinant human USP13 protein in preparation of a drug for treating diabetic cardiomyopathy, and belongs to the technical field of biological medicines.The application first proves that the expression of USP13 in myocardial tissue and serum is significantly reduced under the condition of diabetic cardiomyopathy (DCM); the recombinant human USP13 protein can obviously reduce the level of myocardial cell active oxygen, reduce the expression of NLRP3 inflammasome and active Caspase3 protein in a DCM in-vitro model induced by high sugar / palmitic acid; in a DCM mouse model injected with the recombinant human USP13 protein through a tail vein, myocardial cell apoptosis is inhibited, and the expression of NLRP3 inflammasome and the synthesis of TNF-alpha in the heart of the animal are reduced.USP13 is a human protein, has no obvious toxic side effects, is high in safety, is small in immunological rejection in theory, provides a new effective drug for the clinical treatment of DCM, and has important clinical application value and industrialization prospect.

The disclosure relates to methods of selecting a cancer patient for treatment with an immune checkpoint inhibitor therapy, including assaying a biological sample from a cancer patient for an expression profile of human genes or human proteins encoded by the human genes, wherein the expression profile (i) is identified using a Cross-Species Tumor Immune Microenvironment algorithm, which is based on murine quantitative trait loci (QTL) mapping, and (ii) is associated with immune checkpoint inhibitor response, selecting the cancer patient who has the expression profile for treatment with an immune checkpoint inhibitor therapy, and optionally administering the immune checkpoint inhibitor therapy to the cancer patient.

The disclosure provides agents and methods for preventing or treating diseases associated with one or more antigens. The agents of the invention comprise RNA encoding chimeric proteins comprising an antigenic region. The antigenic region comprises one or more disease-associated antigens, immunogenic variants of fragments thereof. According to the invention, the chimeric proteins, in addition to the antigenic region, comprise a transmembrane domain and cytoplasmatic region, one or both of which are derived from a MHC-I homolog non-native to an organism from which the antigen originates.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein- based building block. In particular, the at least one protein-based building block comprised in the molecule of the technology: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; and e) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5x10-4 mol / litre.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block.In particular, the at least one protein-based building block comprised in the molecule of the technology:a) comprises at least one conjugation site or attachment point;b) has a molecular mass of 2.5 to 70 kDa;c) has a globular three-dimensional (3D) structure;d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; ande) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5×10−4 mol / litre·ft

The disclosed methods relate to a strategy for producing ground truth quantification ratios (both synthetic knockouts and simulated dose response gradients) using synthetic peptides mixed with a human proteome background. These, synthetic, bespoke proteins serve as a built in quality control for sample preparation for proteomics workflows. Additionally, mixtures of synthetic peptides are combined to form assembled synthetic proteins that can be spiked into samples at the start of processing (e.g., trypsin digesting, purification, etc.). In this way, problems in processing methods can be discovered. Sequences can be engineered to inform how well samples are being processed.

The application discloses a kind of digital signal amplification immunodetection method and system based on surface open magnetic bead array.The method is to construct open surface magnetic bead array on transparent flexible substrate using external magnetic field, while combining reciprocating flow microfluidic technology to accelerate antigen-antibody binding reaction, adopt tyramide signal amplification strategy to realize in situ fluorescence deposition, and combine deep learning-based image recognition algorithm to automatically identify positive magnetic beads, realize quantitative analysis.The method has a significant advantage of high sensitivity and rapid detection with a detection sensitivity of fg / mL order and a detection time of less than 20 minutes.The system includes a magnetic field generation module, a reciprocating flow driving module, an enzymatic signal amplification module, an optical acquisition module and an AI recognition module.It can be used for ultra-sensitive quantitative detection of various human proteins, inflammatory factors, viral antigens and other low-abundance biomarkers.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein- based building block. In particular, the at least one protein-based building block comprised in the molecule of the technology: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; and e) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5x10-4 mol / litre.

The present invention provides a peptide that specifically binds to cells constituting cancer, and a pharmaceutical composition containing the peptide. The present invention is a cancer targeting peptide containing a peptide that binds to cancer cells and that comprises one or more amino acid sequences, each identical to a partial region of a human protein selected from the group consisting of extracellular matrix-constituting proteins, transcriptional regulators, nuclear regulators, signaling pathway proteins, and RNA regulatory proteins. The partial region comprises 5-7 amino acid residues.

The invention relates to the field of molecular biology and biological medicine, and particularly discloses an antithrombotic effect of Meteorin protein or gene. Experiments prove that after Meteorin protein is incubated, the platelet aggregation reaction can be remarkably inhibited, the platelet spreading area can be reduced, blood clot contraction can be delayed, and meanwhile ATP release and alpha particle release of platelets and activation of surface integrin alpha IIb beta 3 can be inhibited. In a whole thrombus experiment, the Meteorin protein can effectively inhibit the formation of arterial thrombosis. The Meteorin protein is a human endogenous protein, so that the Meteorin protein has relatively small side effects, has relatively high safety as a potential drug, and has a good industrialization prospect.

The present disclosure provides compositions and methods that utilize a target protein capable of binding a small molecule to form a complex and a binding member that specifically binds the complex, wherein the target protein is derived from a non-human protein and the small molecule is an inhibitor of the non-human protein. The non-human protein can be derived from a viral, bacterial, fungal, or protozoal protein. These compositions and methods allow for controlled interaction of polypeptides fused to the target protein and the binding member, respectively, and can be used to control the activity of dimerization-inducible proteins, such as split transcription factors and split chimeric antigen receptors, by the addition of the small molecule. The present disclosure provides expression vectors, binding members, dimerization-inducible proteins, nucleic acids, cells, viral particles, kits, systems, and methods involving these components.

The invention relates to an application of a polypeptide Nod1-T9 in preparation of drugs for treating acute myocardial infarction diseases. The amino acid sequence of the polypeptide Nod1-T9 is as shown in SEQ ID NO: 1. The invention provides a bioactive polypeptide Nod1-T9 derived from a human protein Nod-1, and the polypeptide Nod1-T9 is derived from a Nod-1 key functional region, has a bioactive mechanism for regulating expression of cell inflammatory factors and resisting fibrosis, and shows excellent treatment potential in intervening cardiac remodeling and heart failure after myocardial infarction. The traditional Chinese medicine composition has anti-inflammatory and anti-fibrosis effects at the same time. The invention is derived from human body, has high safety, is derived from protein naturally existing in human body, has good immunogenicity, and has small expected toxic and side effects. The structure is stable, production is easy, the polypeptide chain is short, the structure is simple, and industrial large-scale chemical synthesis and optimization modification are facilitated.

The present technology relates to the field of drug delivery and provides a molecule comprising or consisting of at least one protein-based carrier building unit, wherein the protein-based carrier building unit comprises at least one, preferably at least two attachment points or conjugation sites. In particular, the present technology provides a molecule comprising at least one protein-based building unit, wherein the at least one protein-based building unit: a) comprises at least one conjugation site or attachment point; b) has a molecular weight of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in aqueous solution at room temperature; and does not specifically bind to any human protein or binds to one or more human proteins with a K D value of more than 5 x 10 ‑4 mol / liter, wherein the molecule further comprises at least one nuclear localization sequence (NLS) covalently linked to the at least one conjugation site or attachment point comprised in the protein-based carrier building unit, directly or via a linker, wherein the NLS preferably comprises or consists of SEQ ID NO: 221.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier component, the protein-based carrier component comprising at least one, preferably at least two, attachment or conjugation sites. In particular, the present technology provides molecules comprising at least one protein-based component, the at least one protein-based component a) comprising at least one conjugation site or attachment site, b) having a molecular weight of 2.5 to 70 kDa, c) having a globular three-dimensional (3D) structure, and d) having a solubility of 10 mg / mL or more measured in aqueous solution at room temperature, and not specifically binding to any human protein or having a solubility of 5×10 - K above 4 moles / liter D The present invention provides a molecule that binds to one or more human proteins at a specific value.

The invention provides a novel class of clearable, tumor-targeting and human protein-based MRI nanoprobes and contrast agents and their compositions, and methods of preparation and use thereof.

The invention discloses recombinant humanized III-type collagen as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The amino acid sequence of the recombinant humanized III-type collagen is any one of SEQ ID No.2-6. The recombinant humanized III-type collagen is a recombinant humanized III-type collagen. Compared with a traditional extraction method, the amino acid sequence of the recombinant protein is highly consistent with that of natural protein of a human body, biological safety risks such as pathogens and prions possibly existing in the animal source extraction process are completely avoided, and meanwhile the recombinant protein has lower immunogenicity. And the protein effectively maintains the natural biological activity and stability of collagen. When the material is used as a wound dressing, the material can efficiently promote cell migration, spreading and proliferation and accelerate tissue regeneration and wound healing, and meanwhile, the material has excellent biocompatibility, controllable degradability and low immunogenicity.

The application belongs to the technical field of biomedicine, and discloses a colorectal cancer prediction model based on cluster molecules and application. The application uses an open shared human protein database and a TCGA public database, carries out intersection analysis by using a machine learning method, screens out a specific molecular set of a group of coded proteins that can be detected in blood and indicate the risk of colorectal cancer, and constructs a logistic regression model by using a GEO colorectal cancer data set. The AUC value of the model for predicting the risk of colorectal cancer is 0.962, and the model can accurately distinguish high-risk and low-risk populations in the test set. The application uses multivariate set effects for modeling, plays a role of multivariate common screening, greatly improves the prediction accuracy and sensitivity of the model, and is simple in the hematological screening method and suitable for popularization in clinical application.

The invention provides a tissue targeting nano antibody and application thereof, and relates to the technical field of biological medicine and gene therapy. Membrane proteins (including an L-type calcium ion channel protein alpha2delta subunit CACNA2D1, a sodium ion channel protein alpha subunit SCN5A, a vascular epicardial substance BVES, a coxsackie virus adenovirus receptor CAR and the like) highly expressed in the heart and skeletal muscle are selected as targets, and a nano antibody synthesis library is used for screening. A series of nano antibodies with tissue targeting are successfully obtained by means of high-throughput sequencing, streaming and the like. The nano antibodies not only can be combined with target spots with high affinity, but also can effectively load and deliver proteins or nucleic acids, so that the enrichment amount and the treatment efficiency of the drugs in target tissues are remarkably improved, and a basis is provided for developing an efficient and safe DMD precise treatment scheme.

The application discloses a method for producing recombinant human proteins in industrial microorganisms, comprising the following steps: introducing a gene coding alpha synuclein into corynebacterium glutamicum by genetic engineering technology to realize expression of the alpha synuclein; and isolating the alpha synuclein in liquid droplet-like membraneless organelles by liquid-liquid phase separation technology to further improve protein yield. Compared with the most widely used Escherichia coli expression system, the method has the following advantages: the method uses corynebacterium glutamicum as a new type of chassis cell, and overcomes problems such as endotoxin pollution and insoluble inclusion body formation in a traditional Escherichia coli expression system; the method significantly improves the yield of alpha synuclein by applying liquid-liquid phase separation technology; the method is not only suitable for the production of alpha synuclein, but also can be popularized to other difficult-to-express proteins, and provides a new technical path for the field of biological pharmacy.